Suppr超能文献

医疗保险受益人群中慢性肾脏病和肺动脉高压患者的死亡率、肾衰竭和住院率。

Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension.

机构信息

Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Institute of Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; VA Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Houston, Texas.

Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas.

出版信息

Am J Kidney Dis. 2021 Nov;78(5):700-708.e1. doi: 10.1053/j.ajkd.2021.02.336. Epub 2021 Apr 24.

Abstract

RATIONALE & OBJECTIVE: Pulmonary hypertension (PH) is highly prevalent among patients with chronic kidney disease (CKD) not requiring kidney replacement therapy. We studied the associations of PH with mortality, kidney failure, as well as cardiovascular (CV) and non-CV hospitalization among Medicare beneficiaries with a CKD diagnosis.

STUDY DESIGN

Retrospective, observational study using a matched cohort design.

SETTING & PARTICIPANTS: Patients with PH (based on 2 claims within 2 years) and patients without PH matched on CKD stage from the Medicare 5% CKD sample (1996-2016).

PREDICTOR

Presence of pulmonary hypertension.

OUTCOME

Mortality, kidney failure, and all-cause, CV, and non-CV hospitalization.

ANALYTICAL APPROACH

Cox proportional hazards models to assess the association between PH and mortality, adjusting for age, sex, race, and comorbidities. Death was considered as a competing event in Fine-Gray models to assess the association between PH and kidney failure. Negative binomial model was used to evaluate the relationship between PH and all-cause, CV, and non-CV hospitalizations.

RESULTS

30,052 patients with PH and CKD and 150,260 CKD stage-matched patients without diagnosed PH were studied. The median age of the study population was 80.7 years, 57.8% were women, and 10.3% were African Americans. The presence of PH was associated with an increased risk of mortality after 1 (HR, 2.87 [95% CI, 2.79-2.95]), 2-3 (HR, 1.56 [95% CI, 1.51-1.61]), and 4-5 (HR, 1.47 [95% CI, 1.40-1.53]) years of follow-up, and a higher risk of all-cause, CV, and non-CV hospitalization during the same period. PH was also associated with kidney failure in after 1 and 2-3 years but not after 4-5 years of follow-up evaluation. Patients with PH also experienced higher rates of acute kidney injury (AKI), and AKI requiring dialysis support within 30 and 90 days of AKI.

LIMITATIONS

Reliance on billing codes and lack of echocardiogram or right heart catheterization data CONCLUSIONS: Among older Medicare beneficiaries with a CKD diagnosis not requiring kidney replacement therapy, the presence of PH was associated with an increased risk of mortality, kidney failure, and hospitalization. Understanding of the mechanism of these associations, especially the increased risk of kidney failure, requires further study.

摘要

背景与目的

肺动脉高压(PH)在未接受肾脏替代治疗的慢性肾脏病(CKD)患者中发病率较高。本研究旨在探讨 PH 与医疗保险受益人群 CKD 患者死亡率、肾衰竭以及心血管(CV)和非 CV 住院之间的相关性。

研究设计

回顾性、观察性研究,采用匹配队列设计。

研究场所与参与者

医疗保险 5% CKD 样本中(1996-2016 年),在 2 年内通过 2 次理赔诊断为 PH 的患者(基于索赔)与未诊断 PH 的 CKD 分期相匹配的患者。

预测因子

存在 PH。

结局

死亡率、肾衰竭和全因、CV 和非 CV 住院。

分析方法

采用 Cox 比例风险模型评估 PH 与死亡率之间的相关性,调整年龄、性别、种族和合并症。在 Fine-Gray 模型中,将死亡视为竞争事件,以评估 PH 与肾衰竭之间的相关性。采用负二项式模型评估 PH 与全因、CV 和非 CV 住院之间的关系。

结果

研究共纳入 30052 例 PH 合并 CKD 患者和 150260 例 CKD 分期相匹配且未诊断 PH 的患者。研究人群的中位年龄为 80.7 岁,57.8%为女性,10.3%为非裔美国人。PH 患者在随访 1 年(HR,2.87 [95%CI,2.79-2.95])、2-3 年(HR,1.56 [95%CI,1.51-1.61])和 4-5 年(HR,1.47 [95%CI,1.40-1.53])后死亡率风险增加,同期全因、CV 和非 CV 住院风险也更高。PH 患者在 1 年和 2-3 年时也与肾衰竭相关,但在 4-5 年随访评估时无相关性。PH 患者还经历了更高的急性肾损伤(AKI)发生率,以及 AKI 后 30 天和 90 天内需要透析支持的 AKI。

局限性

依赖于计费代码,缺乏超声心动图或右心导管检查数据。

结论

在未接受肾脏替代治疗的老年医疗保险受益人群中,存在 PH 与死亡率、肾衰竭和住院风险增加相关。需要进一步研究这些相关性的机制,尤其是肾衰竭风险增加的机制。

相似文献

3
Pulmonary Hypertension Subtypes and Mortality in CKD.慢性肾脏病相关肺动脉高压的亚型与死亡率
Am J Kidney Dis. 2020 May;75(5):713-724. doi: 10.1053/j.ajkd.2019.08.027. Epub 2019 Nov 12.
5
Readmission and Mortality After Hospitalization With Acute Kidney Injury.急性肾损伤住院后的再入院和死亡率。
Am J Kidney Dis. 2023 Jul;82(1):63-74.e1. doi: 10.1053/j.ajkd.2022.12.008. Epub 2023 Apr 27.

本文引用的文献

2
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
4
Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.慢性肾脏病患者肺动脉高压的诊断与治疗。
Am J Kidney Dis. 2020 Jun;75(6):935-945. doi: 10.1053/j.ajkd.2019.12.005. Epub 2020 Mar 19.
5
Pulmonary Hypertension Subtypes and Mortality in CKD.慢性肾脏病相关肺动脉高压的亚型与死亡率
Am J Kidney Dis. 2020 May;75(5):713-724. doi: 10.1053/j.ajkd.2019.08.027. Epub 2019 Nov 12.
6
Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.超越肺部:肺动脉高压的系统性表现。
Am J Respir Crit Care Med. 2020 Jan 15;201(2):148-157. doi: 10.1164/rccm.201903-0656CI.
7
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.卡格列净与 2 型糖尿病和肾病患者的肾脏结局。
N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验